Identify Patients

In asymptomatic or minimally symptomatic mCRPC patients, treat them early with PROVENGE Immunotherapy

6 month duration

Treat early

  • To stimulate your mCRPC patients’ immune systems while they have a lower tumor burden1

NCCN category 1 recommendation

  • NCCN guidelines maintain PROVENGE as a first-line treatment and a prominent category 1 designation2
  • NCCN guidelines support the use of PROVENGE before enzalutamide, abiraterone, chemotherapy, and other treatments in asymptomatic or minimally symptomatic mCRPC patients2

PROVENGE does not preclude the use of subsequent therapies2,3

*Radiographic evidence of disease progression or rising prostate-specific antigen (PSA).
ADT=androgen deprivation therapy; mCRPC=metastatic castrate-resistant prostate cancer; NCCN=National Comprehensive Cancer Network.

Most CRPC patients fit in the PROVENGE window at the time of metastatic diagnosis

6 month duration

Treat early — make sure your patients take advantage of the PROVENGE window

Keep in mind that if your patient:

Candidate for Provenge

He may be a candidate for PROVENGE3

*Radiographic evidence of disease progression or rising PSA.

Learn about Mike's experience with PROVENGE

REFERENCES:

  1. Madan RA, Gulley JL, Fojo T, Dahut WL. Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression. Oncologist. 2010;15(9):969-975.
  2. National Comprehensive Cancer Network. Prostate Cancer. NCCN Clinical Practice Guidelines in Oncology. V2.2016. www.nccn.org. Accessed February 26, 2016.
  3. Provenge [prescribing information]. Seatlle, WA: Dendreon Pharmaceuticals; 2014.
  4. Data on file. n = 511 charts pulled between April 2012 and March 2013 from ~74 practices. Dendreon Pharmaceuticals.
See More
INDICATION

PROVENGE® (sipuleucel-T) is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate-resistant (hormone-refractory) prostate cancer.

IMPORTANT SAFETY INFORMATION

Acute Infusion Reactions: Acute infusion reactions (reported within 1 day of infusion) may occur and include nausea, vomiting, fatigue, fever, rigor or chills, respiratory events (dyspnea, hypoxia, and bronchospasm), syncope, hypotension, hypertension, and tachycardia.

Thromboembolic Events: Thromboembolic events, including deep venous thrombosis and pulmonary embolism, can occur following infusion of PROVENGE. The clinical significance and causal relationship are uncertain. Most patients had multiple risk factors for these events. PROVENGE should be used with caution in patients with risk factors for thromboembolic events.

Vascular Disorders: Cerebrovascular events (hemorrhagic/ischemic strokes and transient ischemic attacks) and cardiovascular disorders (myocardial infarctions) have been reported following infusion of PROVENGE. The clinical significance and causal relationship are uncertain. Most patients had multiple risk factors for these events.

Handling Precautions: PROVENGE is not tested for transmissible infectious diseases.

Concomitant Chemotherapy or Immunosuppressive Therapy: Chemotherapy or immunosuppressive agents (such as systemic corticosteroids) given concurrently with the leukapheresis procedure or PROVENGE has not been studied. Concurrent use of immune-suppressive agents may alter the efficacy and/or safety of PROVENGE.

Adverse Reactions: The most common adverse reactions reported in clinical trials (≥ 15% of patients receiving PROVENGE) were chills, fatigue, fever, back pain, nausea, joint ache, and headache.

Click here for full Prescribing Information.